Oppenheimer & Co. 降低了其在Protara治疗学的股份, 但分析师仍然建议使用“Buy”。 Oppenheimer & Co. reduced its stake in Protara Therapeutics, but analysts still recommend a "Buy."

奥本海默公司(Oppenheimer & Co.)在第一季度将其在Protara治疗疗法中的股份所有权减少了7.4%,出售了14 862个股份,拥有该公司的大约0.51%。 Oppenheimer & Co. reduced its share ownership in Protara Therapeutics by 7.4% in the first quarter, selling 14,862 shares to own about 0.51% of the company. 尽管最近股票价格在一年内波动从160美元到10.48美元不等,分析家仍给予Protara治疗学平均“Buy”评分,12个月的价格目标是20.50美元。 Despite recent share price fluctuations, ranging from $1.60 to $10.48 within a year, analysts have given Protara Therapeutics an average "Buy" rating with a 12-month price target of $20.50. 该公司正在开发TARA-002,这是一个治疗癌症和罕见疾病的细胞疗法,目前正在第二阶段试验中。 The company is developing TARA-002, a cell therapy for cancers and rare diseases, currently in Phase II trials.